Rhizotomy Overview
Rhizotomy is a neuroablative procedure that selectively destroys nerve roots to interrupt pain transmission, most commonly used for trigeminal neuralgia and cancer-related pain, with percutaneous radiofrequency thermocoagulation being the gold standard technique offering 97.6% acute pain relief but requiring repeat procedures in many patients over time.
Procedure Techniques
Rhizotomy can be performed through multiple approaches:
Percutaneous Methods
Radiofrequency thermocoagulation (RF-TR): A 22-gauge spinal needle is advanced through the foramen ovale under fluoroscopic guidance to reach the trigeminal cistern. The procedure uses controlled heating at 75°C for 60 seconds to create selective nerve lesions 1, 2. Patient cooperation is essential during the procedure, requiring only benzodiazepines and narcotic analgesics rather than general anesthesia to allow intraoperative sensory testing 1.
Glycerol rhizotomy: Uses chemical ablation via glycerol injection into Meckel's cave. Real-time fluoroscopic guidance allows needle placement within an average of 11 minutes 3. This technique eliminates the need for intraoperative confirmatory sensory testing 4.
Open surgical rhizotomy: Direct surgical exposure and sectioning of nerve roots, typically reserved for specific cancer pain scenarios 5.
Primary Indications
Trigeminal Neuralgia (Most Common)
- Medically refractory cases failing pharmacotherapy
- Patients who are poor surgical candidates for microvascular decompression due to advanced age or comorbidities 3
- Affects maxillary (V2) branch in 76% and mandibular (V3) branch in 24% of cases 2
Cancer Pain (Evidence-Based Guidelines)
The 2021 Congress of Neurological Surgeons guidelines provide Level III recommendations for rhizotomy in specific cancer pain scenarios 5:
Unilateral somatic nociceptive/neuropathic body cancer pain: Both percutaneous RF/chemical and open surgical rhizotomy may be used, though sensory deficits are expected outcomes and motor/autonomic deficits may occur depending on nerves ablated 5
Craniofacial cancer pain: Cranial nerve rhizotomy is an option alongside trigeminal tractotomy and nucleus caudalis DREZ 5
Other Applications
- Degenerative lumbar facet joint syndrome (full-endoscopic approach) 6
- Spastic cerebral palsy (dorsal rhizotomy) 7
Effectiveness and Pain Relief Duration
Trigeminal Neuralgia Outcomes
Radiofrequency thermocoagulation demonstrates superior long-term durability compared to glycerol rhizotomy:
RF-TR: 97.6% achieve acute pain relief 1. Long-term success rates: 92% at 5 years (including repeat procedures), 94.2% at 10 years, and 100% at 20 years when repeat procedures are included 1. With single procedure only: 57.7% at 5 years, 52.3% at 10 years, 41% at 20 years 1.
Glycerol rhizotomy: 76.9% achieve immediate pain relief, but only 43.4% maintain long-term relief 8. Durability drops significantly: 80% at 6 months, 67% at 1 year, 46% at 2 years, 19% at 5 years, and only 7% at 10 years 8. This represents substantially inferior long-term outcomes compared to RF-TR.
Recent 2025 data confirms RF-TR efficacy: VAS scores decreased from 8.04 to 2.58 at 6 months with patient satisfaction scores improving from 5.60 to 1.92 (p<0.001) 2.
Predictive Factors for Success
- Pre-operative carbamazepine use (HR: 0.52, p=0.025) predicts improved long-term relief 8
- Achieving effective immediate pain relief (HR: 0.33, p<0.001) strongly predicts sustained benefit 8
Cancer Pain Outcomes
The CNS guidelines note that neuroablative procedures including rhizotomy provide pain control in refractory cancer pain, though specific duration data varies by cancer type and location 5.
Complications and Safety Profile
Common Complications (RF-TR from largest series)
- Facial numbness/hypoesthesia: 32-40% transient, 28.3% permanent 1, 2
- Diminished corneal reflex: 5.7% 1
- Masseter weakness/paralysis: 4.1-14% 1, 2
- Dysesthesia: 1-6% 1, 2
Serious but Rare Complications
- Anesthesia dolorosa: 0.8-2.3% 8, 1
- Keratitis: 0.6% 1
- Transient cranial nerve III/VI palsy: 0.8% 1
- Permanent cranial nerve VI palsy: 0.13% 1
- Carotid-cavernous fistula, CSF leak, aseptic meningitis: <0.1% each 1
Critical safety note: No mortalities were reported in the largest series of 1,600 patients over 25 years 1. Glycerol rhizotomy shows a 4.5% complication rate 8.
Cancer Pain Considerations
For cancer pain applications, sensory deficits are expected outcomes rather than complications, and motor/autonomic deficits may occur depending on which nerves are ablated 5.
Postoperative Observation Requirements
Immediate Post-Procedure (First 24 Hours)
- Monitor for acute complications: cranial nerve deficits, CSF leak, hematoma formation
- Assess corneal reflex if V1 territory involved
- Evaluate facial sensation and motor function
- Pain assessment using VAS scale
Short-Term Follow-Up (1 Month)
- Formal pain assessment (VAS scoring)
- Patient satisfaction evaluation (PGIC scale)
- Document any persistent sensory changes
- Assess need for medication adjustment or discontinuation 2
Long-Term Surveillance (6 Months and Beyond)
- Pain recurrence monitoring: Early recurrence (<6 months) occurs in 7.7%, late recurrence in 17.4% 1
- Pain recurrence defined as: VAS ≥4 or need for second intervention 2
- Continued assessment for delayed complications (keratitis if corneal reflex affected)
- Plan for potential repeat procedures given recurrence rates
Critical Clinical Pitfalls
Technique selection matters: RF-TR provides significantly better long-term durability than glycerol rhizotomy (92% vs 43.4% long-term relief) 8, 1. Choose RF-TR when long-term control is the priority.
Repeat procedures are often necessary: 24% of patients require multiple procedures for sustained relief 1. Set realistic expectations with patients that this may not be a one-time intervention.
Patient cooperation is mandatory for RF-TR: Avoid general anesthesia to allow intraoperative sensory testing for selective lesioning 1.
Corneal reflex monitoring is essential: When V1 territory is involved, vigilant monitoring prevents keratitis 1.
Cancer pain applications differ: For cancer-related pain, sensory deficits are expected outcomes, not complications to be avoided 5.